• Financial Highlights

Financial Highlights

Sales and Profit

Business Results

Consolidated States of Income (Excerpt)

(millions of yen)
Item 2014/9 2015/9 2016/9 2017/9 2018/9
Sales 69,367 73,538 76,722 86,902 85,209
Operating profit 6,256 7,682 7,424 14,731 10,631
Ordinary profit 6,202 7,151 7,483 14,577 10,284
Net profit 3,639 3,288 2,272 8,463 2,976

Non-Consolidated States of Income (Excerpt)

(millions of yen)
Item 2014/9 2015/9 2016/9 2017/9 2018/9
Sales 63,343 67,000 70,074 79,955 78,569
Operating profit 8,152 10,459 11,999 20,355 16,983
Ordinary profit 8,201 10,352 12,060 20,400 17,049
Net profit 3,621 3,606 1,788 8,595 2,569

Annual Business Summary (Oct 2017 to Sept 2018)

The Maruho Group is on the path toward realizing its Corporate Long-term Vision 2011 “Excellence in Dermatology”, aiming to introduce innovative changes in the care cycle for dermatological diseases (treatment, aftercare, prevention, diagnosis). The Maruho Group has come together as one to work on the first year of its newly launched third Mid-term Plan (Oct 2017 to Sept 2020).

Research and Development

In research and development activities, Maruho promotes interdisciplinary research in collaboration with research institutions in Japan and overseas while focusing on acquiring new drug creation technology to formulate new products that satisfy unmet medical needs.

  • On February 15, 2018, Maruho received marketing and manufacturing approval in Japan for M1180B as an additional dosage of a blood-flow accelerative/skin moisturizing agent.
  • The review is in progress for the New Drug Application (NDA) submitted in the US by Cutanea Life Sciences, Inc. for M5180, as an agent for the treatment of psoriasis vulgaris.
  • On February 27, 2018, joint development company Asahi Kasei Pharma Co., Ltd. submitted an application for the approval of M5210B in Japan as an agent for the treatment of recurrent herpes simplex.
  • Continued Phase 3 development in Japan for M5250, as a treatment for itching caused by atopic dermatitis.
  • In the US, Cutanea Life Sciences, Inc. continues Phase 3 development of CLS001, as an agent for the treatment of rosacea.
  • In the US, Cutanea Life Sciences, Inc. continues Phase 3 development of CLS006, as an agent for the treatment of verruca vulgaris.


  • The Maruho Group is committed to fulfilling our mission and responsibility as a pharmaceutical company by ensuring a stable supply of high quality products.
  • We aim to provide products that are trusted and supported by patients and develop a production system that meets global standards.

Sales and Marketing

  • Based on the direction of information derived from the needs of patients and healthcare providers, Maruho will develop information provision activities not only by conventional sales representatives, but also with systems using digital technologies. In the cosmetics and diagnostics business, we will actively promote development to expand our product lineup according to customer needs.
  • On March 1, 2018, Maruho succeeded manufacturing and marketing approval in Japan from Galderma KK for reduction of malodor generated in cancerous cutaneous ulcers treatment “Rozex Gel” and began marketing the treatment. Maruho will work to further contribute to the improvement of QOL in Cancer patients and their families,
  • On September 13, 2018, Maruho launched blood-flow accelerative/skin-moisturizing agent “Hirudoid Foam” in Japan to expand treatment options and improve adherence for patients suffering from asteatosis and other skin diseases.
  • On September 28, 2018 Maruho succeeded manufacturing and marketing approval in Japan from Galderma KK for acne vulgaris treatment agent “Differin Gel". Maruho began marketing Differin from July 26, 2016. As the manufacturer and distributor of Differin in Japan, Maruho will appropriately provide and collect information and ensure a stable supply of this product.
  • Aiming to contribute to the realization of healthy skin, Maruho launched the Skincare Trinity Kit on March 15, 2018, and Cleansing Emulsion (makeup remover) on April 3, 2018. These are additions to the lineup of products in Maruho’s own cosmetic brand iniks, designed to target improvement of skin barrier functions for people concerned about adult skin problems.
  • On January 22, 2018, Maruho launched in vitro diagnostic “Dermaquick VZV”. Together with marketing our oral and topical therapeutic treatments for herpes zoster (shingles), Maruho will strive to respond widely to needs related to this skin disease.
  • On July 5, 2018 Nestlé Skin Health and Maruho released the renewed itch measurement app “Itch Tracker” for Apple Watch. Maruho acquired exclusive rights in Japan for Itch Tracker which has been developed to collect data on scratching during sleep. With the release of the renewed Itch Tracker, Maruho hopes to improve patient’s adherence to treatment and promote smooth communication between patients and medical staff.

Overseas Business Activities

  • In the US, we are expanding our product lineup and speeding up the pace of our operations. In Europe and Asia, we will develop effective approaches to realize higher quality contributions to patients suffering from skin diseases worldwide.
  • US-based Cutanea Life Sciences, Inc. will focus on marketing penetration for the topical acne vulgaris treatment agent “Aktipak” launched in 2017. In March, 2018, Cutanea Life Sciences, Inc. received commercialization rights for the topical anti-microbial impetigo treatment agent “Xepi”.

Sales Breakdown

Prescription / Non-Prescription Drug Sales

 Breakdown of Sales by Product Line (Prescription drugs vs. others)


Prescription Drug Sales by Therapeutic Category

 Breakdown of Prescription Drugs Sales by Department


Prescription Drug Sales by Dosage Form

Breakdown of Prescription Drugs Sales by Dosage Forms 


Page top